Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Therapeutic Drug Carrier Systems
Impact-faktor: 2.9 5-jähriger Impact-Faktor: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN Druckformat: 0743-4863
ISSN Online: 2162-660X

Volumes:
Volumen 37, 2020 Volumen 36, 2019 Volumen 35, 2018 Volumen 34, 2017 Volumen 33, 2016 Volumen 32, 2015 Volumen 31, 2014 Volumen 30, 2013 Volumen 29, 2012 Volumen 28, 2011 Volumen 27, 2010 Volumen 26, 2009 Volumen 25, 2008 Volumen 24, 2007 Volumen 23, 2006 Volumen 22, 2005 Volumen 21, 2004 Volumen 20, 2003 Volumen 19, 2002 Volumen 18, 2001 Volumen 17, 2000 Volumen 16, 1999 Volumen 15, 1998 Volumen 14, 1997 Volumen 13, 1996 Volumen 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2017020231
pages 65-97

Peroxisome Proliferated Activated Receptors (PPARs): Opportunities and Challenges for Ocular Therapy

Prachi Khatol
Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Central University, University Road, Sagar, Madhya Pradesh 470003, India
Shivani Saraf
Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Central University, University Road, Sagar, Madhya Pradesh 470003, India
Ankit Jain
Institute of Pharmaceutical Research, GLA University, 17km Stone, NH-2, Mathura-Delhi Road P.O. Chaumuhan, Mathura, Uttar Pradesh 281406, India

ABSTRAKT

Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription factors. They exist in three isoforms (PPAR-α, PPAR-β/δ, and PPAR-Υ) in humans, but mainly PPAR-Υ, and they are expressed in retinal epithelial pigment. PPARs are involved in mediating numerous pathological implications in eye such as diabetic retinopathy (DR), choroidal neovascularization (CNV), glaucoma, diabetic macular edema, and other retinal diseases. Peroxisome proliferator-activated receptors are key players in various biological pathways like lipid degeneration, immune regulation, and reactive oxygen species regulation, regulation of vascular endothelial growth factor, matrixmetalloproteinase-9, and docosahexaenoic acid pathway. Based on evidence from clinical investigations, the drugs meant for PPARs could be promising candidates for intraocular therapy. Anti-VEGF therapy, including bevacizumab, ranibizumab, and aptamers (pegaptanib), has been approved for wet age-related macular degeneration (ARMD). Recently, researchers have explored the role of PPAR-γ in ocular pathophysiological processes and PPAR-γ agonists as novel adjuvants in the treatment of eye diseases. PPAR-γ exhibits potential benefits to improve or prevent various vision-threatening eye diseases such as age-related macular degeneration (ARMD), diabetic retinopathy (DR), keratitis, and optic neuropathy. However, PPAR-γ presents challenges and offers opportunities for ocular scientists to bring better outcomes.


Articles with similar content:

Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy
Critical Reviews™ in Immunology, Vol.36, 2016, issue 4
Susanne Michen , Achim Temme
Neutrophil Infiltration and Chemokines
Critical Reviews™ in Immunology, Vol.26, 2006, issue 4
Yoshiro Kobayashi
Targeting Integrins in Cancer
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 3-4
Chiara Pazzagli, Sandra Donnini
Eosinophils, Pin1 and the Response to Respiratory Viral Infection and Allergic Stimuli
Critical Reviews™ in Immunology, Vol.39, 2019, issue 2
Zhong-Jian Shen, James S. Malter
HPLC Levels of Adenosine in Awheto—Indigenous New Zealand Cordyceps robertsii Hooker (Ascomycetes)
International Journal of Medicinal Mushrooms, Vol.10, 2008, issue 1
Kevin Mitchell, Stephen Tauwhare